Abstract
Stereotactic body radiation therapy (SBRT) involves delivery of image-guided, ablative radiation doses to planning treatment volume(s) using sophisticated dosimetric planning and target localization. Early on, clinical investigators pursued SBRT for the treatment of early stage non-small-cell lung cancer, lung and liver oligometastases and spinal metastases. As a result of its clinical efficacy in these disease sites, SBRT has been explored in the management of persistent or recurrent gynecological cancers. This article will consider indications for SBRT application in gynecological cancer management, will reflect on outcomes from key SBRT clinical trials and will discuss new therapeutic roles of SBRT for gynecological cancers.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.